Physician profile
Simon W Beaven
NPI 1205018967
$23,518.30
in general payments reported to CMS, 2019-2025
10 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $46.62 · 2021: $58.96 · 2022: $13.97 · 2024: $110 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $1,028 · Travel and Lodging: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,675.00 |
| Food and Beverage | $1,028.48 |
| Travel and Lodging | $530.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22,983.50 | 2024-2025 | Givlaari |
| Boston Scientific Corporation | $136.27 | 2020-2025 | General - Biliary Devices |
| Pfizer INC. | $130.26 | 2019-2025 | |
| Dova Pharmaceuticals | $124.78 | 2019 | |
| Madrigal Pharmaceuticals | $70.01 | 2025 | Rezdiffra |
| Olympus America INC. | $20.95 | 2025 | Visiglide |
| Apollo Endosurgery US INC | $20.73 | 2021 | |
| Covidien LP | $17.79 | 2020 | |
| Abbvie INC. | $13.19 | 2020 | |
| Travere Therapeutics, INC. | $0.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Beaven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.